Evaluation of Copeptin, Osteopoietin, Renin and Some Physiological Parameters in Patients with Heart Diseases in Samarra City
Keywords:
Heart Disease, Renin, Copeptin, Lipid Profile, Osteopontin
Abstract
The research aimed to evaluate the levels of copeptin, osteopontin, renin, lipid profile, urea, and creatinine in patients with heart disease in Samarra City. Conducted between March and September 2024, the study involved 50 male and female patients with heart diseases, including atherosclerosis, heart failure, and angina pectoris, alongside a control group of 20 healthy individuals aged 59-75. Blood samples were analyzed using ELISA and various biochemical assays. Results revealed significantly higher levels of copeptin, osteopontin, and renin in heart disease patients compared to the control group. Additionally, elevated triglycerides, urea, and creatinine levels were observed. These findings indicate a correlation between elevated hormonal and physiological parameters and heart disease progression.
References
1. Agah, E.; Zardoui, A.; Saghazadeh, A.; Ahmadi, M.; Tafakhori, A.; and Rezaei, N.(2018). Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis. PLoS One. 13:e0190252. doi: 10.1371/journal.pone.0190252.
2. Alradwan, I., AL Fayez, N., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., ... & Tawfik, E. A. (2024). Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging. Pharmaceutics, 16(8), 1037.
3. Alvarez, E.; Cairrao, E.; Morgado, M.; Morais, C. and Verde, I. (2010).Testosterone and cholesterol vasodilation of rat aorta involves L-type calcium channel inhibition. Advances in pharmacological sciences, 2010.
4. Arendse, L. B., Danser, A. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., ... & Sturrock, E. D. (2019). Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacological reviews, 71(4), 539-570.
5. Badimon, J. J., Badimon, L., Fuester, V. (1990). Regrression of atherosclerotic lesion by HDL plasma fraction in the Cholesterol– fed rabbit, Journal of clinical investigation, 85: 1234-1241.
6. Berrougui, H.; Momo, C. N. and Khalil, A. (2012). Health benefits of high-density lipoproteins in preventing cardiovascular diseases. Journal of clinical lipidology, 6(6), 524-533.
7. Burtis, C.A., and Ashwood, E. R. (1999). Textbook of clinical chemistry. 3rd ed. W. B. Saunders Company, Tokyo. pp.: 1034-1054.
8. Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024). Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis. Frontiers in Pharmacology, 15, 1393333.
9. Cohen, A.; Stein, E. M.; Recker, R. R.; Lappe, J. M.; Dempster, D. W.; Zhou, H. and Zwahlen, A. (2013). Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. The Journal of Clinical Endocrinology and Metabolism, 98(5), 1971-1981.
10. Desnick, R. J. (2018). Fabry disease. Nephrology Secrets: First South Asia Edition-E-Book, 289.
11. Gygi, F. R. (2014). Museum objects experiencing the properties of things, Dudley, Sandra H. (ed.). Material Religion, 10(1),115-116.
12. Jenča, D., Melenovský, V., Stehlik, J., Staněk, V., Kettner, J., Kautzner, J., ... & Wohlfahrt, P. (2021). Heart failure after myocardial infarction: incidence and predictors. ESC heart failure, 8(1), 222-237.
13. Kesireddy, V; Tan, Y; Kline, D; Brock, G;Odei, J. B; Kluwe, B; Effoe, V. S; et al. (2019). The association of life’s simple 7 with aldosterone among African Americans in the Jackson heart study. Nutrients, 11(5), 1–17.
14. Liu, G.; Wang, H.; Chu, H.; Yu, J. and Zhou, X. (2017). Functional diversity of topological modules in human protein-protein interaction networks. Scientific reports, 7(1), 1-13.
15. Lok, Z.S. and Lyle, A.N. (2019). Osteopontin in Vascular Disease: Friend or Foe?. Arteriosclerosis, thrombosis, and vascular biology, 39(4), 613-622.
16. Margaritis, M.; Channon, K. M. and Antoniades, C. (2014). Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxidants and redox signaling, 20(8), 1198-1215.
17. Melander, O. (2016). Vasopressin, from regulator to disease predictor for diabetes and cardiometabolic risk. Annals of Nutrition and Metabolism, 68(Suppl. 2), 24-28.
18. Mohammed, O. A., Alghamdi, M., Alfaifi, J., Alamri, M. M. S., Al-Shahrani, A. M., Alharthi, M. H., ... & Doghish, A. S. (2024). The emerging role of miRNAs in myocardial infarction: From molecular signatures to therapeutic targets. Pathology-Research and Practice, 253, 155087.
19. Morgenthaler, N. G. (2010). Copeptin: a biomarker of cardiovascular and renal function. Congestive heart failure, 16: 37-44.
20. Paul, M; Mehr, A. P;and Kreutz, R. (2006). Physiology of local renin-angiotensin systems. Physiological Reviews, 86(3), 747–803.
21. Pencina, M. J.; D’Agostino, R. B.; Zdrojewski, T.; Williams, K.; Thanassoulis, G.; Furberg, C. D. and Sniderman, A. D. (2015). Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European journal of preventive cardiology, 22(10), 1321-1327.
22. Ridgway, N. and McLeod, R. (2015). Biochemistry of lipids, lipoproteins and membranes. Elsevier. 330, 331, 361, 437, 438, 524, 525.
23. Scanlon, V. C. and Sanders, T. (2018). Essentials of anatomy and physiology. FA Davis. chapters 12. 5th ed; 272-288.
24. Shahid, M.; Sun, R. L.; Liu, Y.; Bao, J. L.; Huang, C. X.; Liao, Y. and Zhang, Y. L. (2016). Is high high-density lipoprotein cholesterol beneficial for premature coronary heart disease A meta-analysis. European journal of preventive cardiology, 23(7), 704-713.
25. Siragy, H. M; and Carey, R. M. (2010). Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. American Journal of Nephrology, 31(6), 541–550.
26. Steel, R. and Torries, J. (1980). Principle and Procedures of Statistics :A Biochemical Approach. 2nd edition, McGraw-Hill Book Company Inc., New York, USA.
27. Sureda, X.; Martínez-Sánchez, J. M.; Fu, M., Pérez-Ortuño, R.; Martinez, C.; Carabasa, E. and Fernández, E. (2014). Impact of the Spanish smoke-free legislation on adult, non-smoker exposure to secondhand smoke: cross-sectional surveys before (2004) and after (2012) legislation. PLoS One, 9(2).
28. Tasevska, I.; Enhörning, S.;, M.; Nilsson, P. M. and Melander, O. (2016). Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart, 102(2), 127-132.
29. Tianxin Yang, T; and Xu, C. (2017). Physiology and pathophysiology of the intrarenal renin-angiotensin system: an update. Journal of the American Society of Nephrology, 28(4), 1040-1049.
30. Tietz, N. W. (1999). Textbook of clinical chemistry, 3rd Ed C. A .Burtis, E R Ash wood, W .B. Saunders. pp: 826 -835.
31. Van Bulck, L., Goossens, E., Morin, L., Luyckx, K., Ombelet, F., Willems, R., ... & BELCODAC consortium. (2022). Last year of life of adults with congenital heart diseases: causes of death and patterns of care. European heart journal, 43(42), 4483-4492.
32. Voors, A. A.; Von Haehling, S.; Anker, S. D.; Hillege, H. L.; Struck, J.;Hartmann, O.; Bergmann, A.; et al. (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. European Heart Journal, 30(10), 1187–1194.
33. Yavcini, O.; Askin, L.; Secen, O.; Turkmen, S.; Akturk, E.; Tanriverdi, O. and Dagli, M.N. (2019). Copeptin levels in patients with coronary artery ectasia. Interventional Medicine and Applied Science, 11 (2):112-116.
2. Alradwan, I., AL Fayez, N., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., ... & Tawfik, E. A. (2024). Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging. Pharmaceutics, 16(8), 1037.
3. Alvarez, E.; Cairrao, E.; Morgado, M.; Morais, C. and Verde, I. (2010).Testosterone and cholesterol vasodilation of rat aorta involves L-type calcium channel inhibition. Advances in pharmacological sciences, 2010.
4. Arendse, L. B., Danser, A. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., ... & Sturrock, E. D. (2019). Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacological reviews, 71(4), 539-570.
5. Badimon, J. J., Badimon, L., Fuester, V. (1990). Regrression of atherosclerotic lesion by HDL plasma fraction in the Cholesterol– fed rabbit, Journal of clinical investigation, 85: 1234-1241.
6. Berrougui, H.; Momo, C. N. and Khalil, A. (2012). Health benefits of high-density lipoproteins in preventing cardiovascular diseases. Journal of clinical lipidology, 6(6), 524-533.
7. Burtis, C.A., and Ashwood, E. R. (1999). Textbook of clinical chemistry. 3rd ed. W. B. Saunders Company, Tokyo. pp.: 1034-1054.
8. Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024). Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis. Frontiers in Pharmacology, 15, 1393333.
9. Cohen, A.; Stein, E. M.; Recker, R. R.; Lappe, J. M.; Dempster, D. W.; Zhou, H. and Zwahlen, A. (2013). Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. The Journal of Clinical Endocrinology and Metabolism, 98(5), 1971-1981.
10. Desnick, R. J. (2018). Fabry disease. Nephrology Secrets: First South Asia Edition-E-Book, 289.
11. Gygi, F. R. (2014). Museum objects experiencing the properties of things, Dudley, Sandra H. (ed.). Material Religion, 10(1),115-116.
12. Jenča, D., Melenovský, V., Stehlik, J., Staněk, V., Kettner, J., Kautzner, J., ... & Wohlfahrt, P. (2021). Heart failure after myocardial infarction: incidence and predictors. ESC heart failure, 8(1), 222-237.
13. Kesireddy, V; Tan, Y; Kline, D; Brock, G;Odei, J. B; Kluwe, B; Effoe, V. S; et al. (2019). The association of life’s simple 7 with aldosterone among African Americans in the Jackson heart study. Nutrients, 11(5), 1–17.
14. Liu, G.; Wang, H.; Chu, H.; Yu, J. and Zhou, X. (2017). Functional diversity of topological modules in human protein-protein interaction networks. Scientific reports, 7(1), 1-13.
15. Lok, Z.S. and Lyle, A.N. (2019). Osteopontin in Vascular Disease: Friend or Foe?. Arteriosclerosis, thrombosis, and vascular biology, 39(4), 613-622.
16. Margaritis, M.; Channon, K. M. and Antoniades, C. (2014). Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxidants and redox signaling, 20(8), 1198-1215.
17. Melander, O. (2016). Vasopressin, from regulator to disease predictor for diabetes and cardiometabolic risk. Annals of Nutrition and Metabolism, 68(Suppl. 2), 24-28.
18. Mohammed, O. A., Alghamdi, M., Alfaifi, J., Alamri, M. M. S., Al-Shahrani, A. M., Alharthi, M. H., ... & Doghish, A. S. (2024). The emerging role of miRNAs in myocardial infarction: From molecular signatures to therapeutic targets. Pathology-Research and Practice, 253, 155087.
19. Morgenthaler, N. G. (2010). Copeptin: a biomarker of cardiovascular and renal function. Congestive heart failure, 16: 37-44.
20. Paul, M; Mehr, A. P;and Kreutz, R. (2006). Physiology of local renin-angiotensin systems. Physiological Reviews, 86(3), 747–803.
21. Pencina, M. J.; D’Agostino, R. B.; Zdrojewski, T.; Williams, K.; Thanassoulis, G.; Furberg, C. D. and Sniderman, A. D. (2015). Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European journal of preventive cardiology, 22(10), 1321-1327.
22. Ridgway, N. and McLeod, R. (2015). Biochemistry of lipids, lipoproteins and membranes. Elsevier. 330, 331, 361, 437, 438, 524, 525.
23. Scanlon, V. C. and Sanders, T. (2018). Essentials of anatomy and physiology. FA Davis. chapters 12. 5th ed; 272-288.
24. Shahid, M.; Sun, R. L.; Liu, Y.; Bao, J. L.; Huang, C. X.; Liao, Y. and Zhang, Y. L. (2016). Is high high-density lipoprotein cholesterol beneficial for premature coronary heart disease A meta-analysis. European journal of preventive cardiology, 23(7), 704-713.
25. Siragy, H. M; and Carey, R. M. (2010). Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. American Journal of Nephrology, 31(6), 541–550.
26. Steel, R. and Torries, J. (1980). Principle and Procedures of Statistics :A Biochemical Approach. 2nd edition, McGraw-Hill Book Company Inc., New York, USA.
27. Sureda, X.; Martínez-Sánchez, J. M.; Fu, M., Pérez-Ortuño, R.; Martinez, C.; Carabasa, E. and Fernández, E. (2014). Impact of the Spanish smoke-free legislation on adult, non-smoker exposure to secondhand smoke: cross-sectional surveys before (2004) and after (2012) legislation. PLoS One, 9(2).
28. Tasevska, I.; Enhörning, S.;, M.; Nilsson, P. M. and Melander, O. (2016). Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart, 102(2), 127-132.
29. Tianxin Yang, T; and Xu, C. (2017). Physiology and pathophysiology of the intrarenal renin-angiotensin system: an update. Journal of the American Society of Nephrology, 28(4), 1040-1049.
30. Tietz, N. W. (1999). Textbook of clinical chemistry, 3rd Ed C. A .Burtis, E R Ash wood, W .B. Saunders. pp: 826 -835.
31. Van Bulck, L., Goossens, E., Morin, L., Luyckx, K., Ombelet, F., Willems, R., ... & BELCODAC consortium. (2022). Last year of life of adults with congenital heart diseases: causes of death and patterns of care. European heart journal, 43(42), 4483-4492.
32. Voors, A. A.; Von Haehling, S.; Anker, S. D.; Hillege, H. L.; Struck, J.;Hartmann, O.; Bergmann, A.; et al. (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. European Heart Journal, 30(10), 1187–1194.
33. Yavcini, O.; Askin, L.; Secen, O.; Turkmen, S.; Akturk, E.; Tanriverdi, O. and Dagli, M.N. (2019). Copeptin levels in patients with coronary artery ectasia. Interventional Medicine and Applied Science, 11 (2):112-116.
Published
2024-09-16
How to Cite
Hussain, A. I. (2024). Evaluation of Copeptin, Osteopoietin, Renin and Some Physiological Parameters in Patients with Heart Diseases in Samarra City. Central Asian Journal of Medical and Natural Science, 5(4), 790-797. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/2610
Section
Articles
